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Abstract
Amsacrine is an anilinoacridine derivative anticancer drug, used to treat a wide variety of malignancies. In cells, amsacrine
poisons topoisomerase 2 by stabilizing DNA-drug-enzyme ternary complex. Presence of amsacrine increases the steady-
state concentration of these ternary complexes which in turn hampers DNA replication and results in subsequent cell death.
Due to reversible binding and rapid slip-out of amsacrine from DNA duplex, structural data is not available on amsacrine-
DNA complexes. In the present work, we designed five oligonucleotide duplexes, differing in their minor groove widths and
hydration pattern, and examined their binding with amsacrine using attenuated total reflection Fourier transform infrared
(ATR-FTIR) spectroscopy. Complexes of amsacrine with calf thymus DNA were also evaluated for a comparison. Our results
demonstrate for the first time that amsacrine is not a simple intercalator; rather mixed type of DNA binding (intercalation
and minor groove) takes place between amsacrine and DNA. Further, this binding is highly sensitive towards the geometries
and hydration patterns of different minor grooves present in the DNA. This study shows that ligand binding to DNA could
be very sensitive to DNA base composition and DNA groove structures. Results demonstrated here could have implication
for understanding cytotoxic mechanism of aminoacridine based anticancer drugs and provide directions to modify these
drugs for better efficacy and few side-effects.
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Introduction
Topoisomerase enzymes are ubiquitous in nature because they
play important task of regulation of superhelicity of DNA. Many
biologically significant phenomena like DNA replication, tran-
scription, segregation and recombination required topoisomerase
enzymes [1-3]. In vertebrates, topoisomerase type 1 and type 2 are
found. In its course of action, topoisomerase 2 creates double
strand breaks in opposite strands of DNA, passes an intact segment
of DNA from this transient opening and finally reseals these
openings in DNA. This process, according to need of cell, either
decatenates or changes topological number of DNA by 62 [4–7].
Topoisomerase 2 wrapped DNA fragments are short lived and
generally termed as cleavable complex [8]. Stabilization of these
cleavable complexes by different topoisomerase 2 poisons includ-
ing amsacrine though, results in their accumulation in the cell.
These stabilized ternary complexes act as replication hurdles and
stall the movement of replication machinery [9]. This inhibition of
replication process activates various DNA repair mechanisms but
high steady-state concentrations of these ternary complexes result
in permanent double strand breaks and other mutational errors
which in turn finally lead to cell death [1], [3], [8]. Hence, the
critical phenomenon behind the poisoning of topoisomerase 2 by
different antitumor agents is stabilization of the cleavable
complexes [10].
Amsacrine is the first anilinoacridine based chemotherapeutic
drug (Figure 1), which is used to treat a broad spectrum of
malignancies including acute leukemias and lymphomas [11–13].
Topoisomerase 2 is a natural target of amsacrine and related
compounds in cells and thus forms topoisomerase 2 mediated
double-strand break of DNA [14], [15]. In its course of action,
amsacrine forms ternary complex with DNA and topoisomerase 2.
Recent studies show that amsacrine is sandwiched between DNA
binding sites and topoisomerase 2 enzyme [16], [17]. Thus, in
ternary complexes, topoisomerase 2 and amsacrine share common
binding sites on DNA and amsacrine directs the enzyme’s binding
on the DNA duplex [16], [17]. Therefore, interaction of amsacrine
with DNA duplex is crucial determinant of topoisomerase 2
mediated DNA cleavage pattern.
Despite a direct association between DNA binding properties of
aminoacridine derivatives and topoisomerase 2 toxicity, DNA
adducts of amsacrine and related compounds are not characterize
yet. The major factor behind the difficulty to obtain information
on amsacrine-DNA complexes is reversible binding of amsacrine
to DNA with a transition time of ,1–6 ms [18]. Due to this short
transition time of binding, there is no X-ray crystallographic,
NMR spectroscopy or electrophoresis record available on
amsacrine-DNA complexes. Complete understanding on DNA
binding mechanism of amsacrine could be helpful to resolve many
unrequited questions associated with the amsacrine mediated
topoisomerase 2 toxicity and may also provide an input for new
PLOS ONE | www.plosone.org 1 July 2013 | Volume 8 | Issue 7 | e69933
drug designing. For instance, it is not known why the compounds
which share common aminoacridine chromophore with amsacrine
and differ only by side chains, exhibit different DNA binding
properties and consequently produce very diverse DNA cleavage
patterns induced by topoisomerase 2 [19], [20]. Likewise, o-
AMSA, which is an isomer of m-AMSA (Figure 1) (thus shares
same reactive groups) is biologically inactive [20], [21]. Further, it
is unclear why m-AMSA appears to specifically stimulate DNA
cleavage by Topoisomerase 2 at sites in DNA adjacent to thymine
or adenine residues and whether there is a preference for binding
of the methoxyaniline moiety of the amsacrine in the major or
minor groove [18], [22], [23]. Sequence preference of amsacrine
with DNA binding is also not well defined.
In the present work, we utilized attenuated total reflection–
Fourier transform infrared (ATR-FTIR) spectroscopy technique to
study DNA binding behavior of amsacrine. FTIR spectroscopy has
an edge over other mentioned techniques that it does not require
stable complex formation between ligand and biomolecule
therefore information can be drawn on transiently bound
complexes. FTIR spectroscopy is increasingly used for biomole-
cule-ligand interaction studies and for identification of conforma-
tions of biomolecules [24–29]. High level sensitivity and the
potential to distinguish different conformational sub-states of
biomolecules simultaneously in solutions are the merits of ATR-
FTIR spectroscopy which enabled us to illustrate the detailed
information on DNA binding properties of amsacrine.
Experimental Section
Sample Preparation
Calf thymus DNA (ctDNA) type I (Molar excitation coefficient
e=6600 cm21) and amsacrine were procured from Sigma-Aldrich
chemicals, USA. Five different oligonucleotide duplexes (RP-
HPLC purified), varying in their nucleobases and their sequential
arrangements [(AAAAAAAAAAAA)2 e=174828, (ATATATA-
TATAT)2 e=190086, (TTAATTAATTAA)2 e=182385,
(AGAGCAACAGAG)2 e=189879 and (AGAGACCAGAGA)2
e=193683] were purchased from Eurogenetec, Belgium and
Sigma-Aldrich chemicals, USA. ctDNA and oligonucleotides were
dissolved in 100 mM Tris-HCl buffer (pH 7.4). Concentration of
solutions of ctDNA and duplexes were checked spectrophotomet-
rically using their excitation coefficients as provided by the
manufacturers. The final concentration of ctDNA and duplexes in
their stock solutions was adjusted to 20 mM. Molar ratios (drug/
nucleotide) of 1/10, 1/20 and 1/50 were prepared by incubation
of varying amount of amsacrine with constant ctDNA and duplex
concentrations.
FTIR Spectra
FTIR Spectra were recorded on Bruker Tensor series 32
spectrophotometer. Spectral measurements were performed after
2 hr incubation of amsacrine with ctDNA and duplexes. Freshly
prepared samples were used for all the measurements. The
solution spectra were recorded using MiracleH (Pike) ZnSe HATR
crystal. Two hundred fifty six scans were co-accumulated in the
spectral range of 2400-600 cm21 with a resolution of 2 cm21.
Background atmospheric spectrum was collected before every
measurement. A spectrum of buffer solution was recorded and
subtracted from the spectra of free ctDNA, duplexes and their
complexes with amsacrine to perform water subtraction according
to established procedure [30]. For each measurement, three
independent samples were used and their spectra were subse-
quently averaged to ensure the reproducibility of results. Sample
chamber was continuously purged with dry nitrogen to remove
water vapor. All the spectral measurements were carried out at
room temperature. No data treatment was performed except
multiple baseline correction and normalization for 1085 cm21
band. Second derivatives were calculated using Savitzky-Golay
functionality.
Results
Five dodecamer oligonucleotide duplexes having varied base
sequence were designed: (AAAAAAAAAAAA)2, (ATATATATA-
TAT)2, (TTAATTAATTAA)2, (AGAGCAACAGAG)2, and
(AGAGACCAGAGA)2. These duplexes and ctDNA were incu-
bated with different molar ratios of amsacrine to obtain their
complexes. Wavenumber assignments to IR bands of ctDNA and
oligonucleotides are according to literature [28], [31-34]. Second
derivatives of all the spectra are generated for better differentiation
between overlapping bands and to compare intensity variations.
Spectra of free duplexes show canonical B-DNA conformation.
Though, upon careful examination of the region 950-700 cm21, it
is apparent that duplexes differ slightly in some spectral features.
For instance, spectra of duplex (AGAGCAACAGAG)2 and
(AGAGACCAGAGA)2 exhibit subtle N-type sugar conformation
features (,860 cm21 and ,808 cm21). Presence of these features
is consistent with the given fact that increasing content of G/C
base pairs favor N type sugar conformation in DNA [33], [34].
Spectral presence of these minute features signifies the single
nucleotide level sensitivity of ATR-FTIR approach that is also
supported by some earlier observations [28], [34].
Amsacrine-DNA Complexes
Infrared band at 1714 cm21 in the spectrum of free calf thymus
DNA (ctDNA) is assigned to in-plane stretching vibrations of
guanine and adenine aromatic rings. This band shifts to
1712 cm21 in amsacrine-ctDNA complex at 1/10 molar ratio
(Figure 2). Thymine C2=O2 stretching vibration (with some
contributions of C4=O4 stretching) band assigned at 1664 cm21
and adenine ring stretching band at 1606 cm21, shift to
1660 cm21 and 1603 cm21 respectively in drug-DNA complexes.
These bands also exhibit intensity variations with amsacrine
addition to ctDNA (Figure 3 panel 1). Guanine band (1614 cm21)
and adenine band (1606 cm21) show slight reduction in intensity
while thymine band (1664 cm21) exhibits some increase in
absorbance. Cytosine band ct 1493 cm21 did not exhibit any
appreciable shift though; slight intensity change is observed for this
band ((Figure 3 panel 1)). Moderate shift and intensity changes for
IR bands of adenine thymine base pairs (at 1660 cm21 and
1606 cm21) are assigned to intercalation between these base pairs.
Figure 1. Structure of (a) amsacrine (m-Amsa) and (b) o-Amsa.
doi:10.1371/journal.pone.0069933.g001
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Figure 2. Stacked view of FTIR spectra of ctDNA (a) and its complexes with amsacrine at different molar ratios (r) of 1/50 (b), 1/20 (c)
and 1/10(d).
doi:10.1371/journal.pone.0069933.g002
Figure 3. Overlaid view of second derivative spectra of ctDNA and duplexes with their complexes of amsacrine at molar ratio of 1/
10 (drug/nucleotide). Panel 1: ctDNA (blue) and complex (red), Panel 2: (AAAAAAAAAAAA)2 (blue) and complex (red) (b), Panel 3:
(ATATATATATAT)2 (blue) and complex (red), Panel 4: (TTAATTAATTAA)2 (blue) and complex (red), Panel 5: (AGAGCAACAGAG)2 (blue) and complex
(red), Panel 6: (AGAGACCAGAGA)2 (blue) and complex (red).
doi:10.1371/journal.pone.0069933.g003
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There are well-established infrared marker bands for interca-
lation and groove binding modes of interaction [26], [30], [35],
[36]. Moderate shifts and intensity variations in guanine and
cytosine bands (at 1715 cm21 and 1493 cm21 respectively) are
assigned to intercalation of ligand between these base pairs of
DNA while major groove binding is characterize by change in
intensity and position shift in 1715 cm21 band [26]. Cytosine
band remains intact in this interaction. Similarly, moderate
shifting and intensity changes for infrared marker bands assigned
to adenine thymine base pairs signify intercalation between these
base pairs. Thymine oxygen group (C2=O2) is present in minor
groove of DNA. Stretching vibrations of this group is assigned
around 1690 cm21 in the infrared region which is a specific
marker for minor groove binding interaction [35], [36]. Any
ligand interaction at minor groove results in intensity changes for
this peak. Intercalation does not affect the peak.
In the amsacrine-DNA complexes, a low intensity band around
1692 cm21 is evident at 1/10 amsacrine DNA molar ratio
(Figure 2). This band is overlapped by surrounding high intensity
bands around 1712 and 1660 cm21; however it is clear in the
second derivative spectra (Figure 3 panel 1). As aforementioned,
this band is specifically assigned to vibrations of thymine C2=O2
moiety, which lies in DNA minor groove [35], [36]. Changes in
this band are associated with ligand interaction (through hydrogen
bond probably) with thymine C2=O2 group present in the minor
groove of DNA [35], [36].
Phosphate asymmetric and symmetric stretching bands
(1224 cm21 and 1086 cm21 respectively) and sugar stretching
band at 1052 cm21 do not show appreciable shift in complexes,
though at high drug ratios, some variations are observed. Infrared
band at 969 cm21 and 935 cm21 are assigned to DNA backbone
and considered as B-form markers of DNA (Figure 2, Figure 4
panel 1). We observe slight deviations for these two bands in the
amsacrine-ctDNA complexes. Deoxyribose sugar ring vibrations
produce a band at 896 cm21 which shifts to 895 cm21 in
amsacrine-ctDNA complexes. Band at 837 cm21 is the sensitive
marker band of sugar pucker in S (C29-endo/anti) type
conformation (global B-DNA conformation) [31]. This band splits
into two bands at 836 cm21 and 824 cm21 in the complexes
(Figure 3, 4 panel 1). Formation of the new band at 824 cm21 is
indicative of some N type (C39-endo/anti) sugar conformation (A-
DNA conformation) features in amsacrine-ctDNA complexes [31],
[33]. Occurrence of N type sugar conformation is further
confirmed by the presence of a shoulder around 861 cm21 in
the complexes (Figure 3, 4 panel 1) [31], [34].
Amsacrine- Duplex Complexes
Amsacrine-(AAAAAAAAAAAA)2 complex. Shifts and inten-
sity changes are observed for major bands assigned to adenine and
thymine in plane ring vibrations in base stacking region. Band at
1715 cm21 and 1607 cm21, assigned to adenine ring vibrations,
shift to 1710 cm21 and 1604 cm21 respectively in the complexes
(Figure 5). Thymine band assigned at 1653 cm21 shifts to
1658 cm21 in the amsacrine-duplex complexes. Presence of new
band around 1691 cm21 (thymine C2=O2 in minor groove) is
apparent in second derivative spectra of complexes (Figure 3 panel
2). Minor variations are observed in second derivative spectra for
the bands in base-sugar region.
IR band at 968 cm21 (sugar-phosphate backbone) shows slight
deviation in amsacrine-duplex complexes. IR band at 839 cm21 (S
type conformation) splits into two bands at 842 cm21 and
824 cm21 in amsacrine-duplex complexes (Figure 3, 4 panel 2).
Spectral features of N type sugar pucker are more intense for these
amsacrine-duplex complexes compared to amsacrine-ctDNA
complexes.
Amsacrine-(ATATATATATAT)2 complex. Changes ob-
served for amsacrine-(ATATATATATAT)2 complexes are similar
to those observed for amsacrine-(AAAAAAAAAAAA)2 complexes
(Figure 6, Figure 3, 4 panel 3). Only difference in both the
complexes comes from the base-phosphate region where added
intensity variations are evident for (ATATATATATAT)2 duplex
than the (AAAAAAAAAAAA)2 duplex upon interaction with
amsacrine.
Amsacrine-(TTAATTAATTAA)2 complex. Compared to
other complexes of amsacrine, amsacrine-(TTAATTAATTAA)2
complexes do not show any noticeable shift in band positions and
intensity variation in all the major infrared bands (Figure 7,
Figure 3 panel 4).
Most of the bands remain unaffected in amsacrine-(TTAAT-
TAATTAA)2 complexes. Bands at 1713 cm21, 1660 cm21 and
1606 cm21 show insignificant deviations even at the highest
concentration used in the experiment. Consistent to other bands,
sugar band at 840 cm21 does not exhibit any change in the
spectra of complexes (Figure 3, 4 panel 4).
Amsacrine-(AGAGCAACAGAG)2 complex. IR band at
1713 cm21 (guanine and adenine) marginally shifts in its position
with intensity variations in the complexes (Figure 8). Adenine band
at 1664 cm21 shifts to 1662 cm21 and thymine band at
1604 cm21 shifts to 1606 cm21 with some intensity changes in
the spectra of amsacrine-duplex complexes. Induction of N type
sugar conformation is evident by increase in the intensity of bands
at 861 cm1 and 821 cm21 in the complexes (Figure 3, 4 panel 5).
Other infrared bands show negligible shift or remains unchanged.
Amsacrine-(AGAGACCAGAGA)2 complex. This duplex
shows similar variations in its complexes which was observed for
amsacrine-(AGAGCAACAGAG)2 complexes (Figure 9). Some
bands for example, in the sugar-base region (1500-1250 cm21),
show slight deviations compared to (AGAGCAACAGAG)2
duplex in the complexes (Figure 3, 4 panel 6).
Discussion
The present study was designed to systematically evaluate the
sequence and groove preferences of amsacrine with DNA. Binding
preference of amsacrine for (ATATATATATAT)2 and
(AAAAAAAAAAAA)2 duplexes is apparent from these ATR-
FTIR spectroscopic results. Evidence for this comes from the
major shift and intensity variation for the bands assigned to in-
plane ring vibrations of adenine and thymine at 1715 cm21,
1653/1663 cm21 and 1607 cm21 (Figure 5, 6, Figure 3 panel 2,
3). These changes in IR bands specify intercalation of aminoacri-
dine chromophore of amsacrine between A/T base pairs.
Intercalation is further confirmed for these duplexes by intensity
changes and minor shifts in less sensitive markers for adenine and
thymine at 1578 cm21 and 1484 cm21 (Figure 3 panel 2 and
panel 3) in these duplexes. Intercalation generally affects the ring
stretching vibrations of nitrogenous bases, which in turn result in
intensity variations and shifting of peak positions. Changes in the
thymine C2=O2 band vibrations at 1653/1663 cm21 and
presence of a new band around 1692 cm21 (Figure 3), further
indicate the binding of amsacrine with this group in the minor
groove. This band (, 169221) is a specific marker for minor
groove interaction [35,36]. Sulfonamide side chain of amsacrine is
undoubtedly assigned as topoisomerase 2 binding domain [37],
[38] and while acridine chromophore inserts between base pairs
only methoxyaniline moiety remains to bind with this thymine
group (C2=O2) lying in the DNA minor groove. In the minor
Minor Groove Width on Amsacrine-DNA Interaction
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Figure 4. Close-up view of the FTIR spectra of ctDNA and duplexes with their complexes of amsacrine at 1/10 molar ratio (drug/
nucleotide) in the 950-700 cm21 spectral range. Panel 1: ctDNA (a) and complex (b), Panel 2: (AAAAAAAAAAAA)2 duplex (a) and complex (b),
Panel 3: (ATATATATATAT)2 duplex (a) and complex (b), Panel 4: (TTAATTAATTAA)2 duplex (a) and complex (b), Panel 5: (AGAGCAACAGAG)2 duplex
(a) and complex (b), Panel 6: (AGAGACCAGAGA)2 duplex (a) and complex (b).
doi:10.1371/journal.pone.0069933.g004
Figure 5. Stacked view of FTIR spectra of (AAAAAAAAAAAA)2 duplex (a) and its complexes with amsacrine at different molar ratios
(r) of 1/50 (b), 1/20 (c) and 1/10 (d).
doi:10.1371/journal.pone.0069933.g005
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Figure 6. Stacked view of FTIR spectra of (ATATATATATAT)2 duplex (a) and its complexes with amsacrine at different molar ratios
(r) of 1/50 (b), 1/20 (c) and 1/10 (d).
doi:10.1371/journal.pone.0069933.g006
Figure 7. Stacked view of FTIR spectra of (TTAATTAATTAA)2 duplex (a) and its complexes with amsacrine at different molar ratios
(r) of 1/50 (b), 1/20 (c) and 1/10 (d).
doi:10.1371/journal.pone.0069933.g007
Minor Groove Width on Amsacrine-DNA Interaction
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Figure 8. Stacked view of FTIR spectra of (AGAGCAACAGAG)2 duplex (a) and its complexes with amsacrine at different molar ratios
(r) of 1/50 (b), 1/20 (c) and 1/10 (d).
doi:10.1371/journal.pone.0069933.g008
Figure 9. Stacked view of FTIR spectra of (AGAGACCAGAGA)2 duplex (a) and its complexes with amsacrine at different molar ratios
(r) of 1/50 (b), 1/20 (c) and 1/10 (d).
doi:10.1371/journal.pone.0069933.g009
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groove, weak interactions like hydrogen bonding and van der
Waals interactions could stabilize the methoxyaniline moiety.
Interestingly, in comparison to these two duplexes, amsacrine
shows very weak binding with (TTAATTAATTAA)2 duplex
which has the same number of A/T base pairs and differs only by
their sequential arrangements. Intensity variation for band at
1660 cm21 (thymine C2=O2) is almost negligible for amsacrine-
(TTAATTAATTAA)2 complexes compared to other two duplex-
es (Figure 7, Figure 3 panel 4). Consistent to other bands, sugar
pucker marker bands also remains unaffected in its complexes with
amsacrine (Figure 3, 4 panel 4). this differences in interaction
arises due to differences in groove structures and geometries.
Sequences that contain four or more AAAA or ATAT are
classified as A-tracts or A-steps. These A-tract sequences comprise
narrow minor groove with single or double spine of bound water
[39]. A-tracts have negative roll angles and propeller twists, which
further compress the minor groove [39]. these sequences are
highly favored by minor groove binders. In contrast to A-tracts,
steric clash of the cross-strand adenines occurs in TA steps (in
TTAA and TATA repeat sequences), which widens the minor
groove [39], [40]. Therefore, TA steps are disruptive for minor
groove interaction by ligands. It is established that different minor
groove binding ligands interact with AAAA and AATT sequences
much stronger than TTAA and TATA sequences [41]. Due to
weak van der Waals interactions, binding enthalpy should be
inferior for shallow minor grooves of TTAA repeat sequence
compared to deep grooves of ATAT and AAAA sequences.
Moreover, lack of spine of bound water is also an important factor,
which precludes binding of minor groove ligands with TTAA
repeat sequences. Minor groove binders are highly specific about
groove structure and their hydration pattern, therefore differential
binding of amsacrine with (AAAAAAAAAAAA)2/(ATATATA-
TATAT)2 and (TTAATTAATTAA)2 suggests the position of
methoxyaniline moiety in the minor groove. Methoxyaniline
moiety provides discriminating factor of amsacrine between
different minor grooves while acridine chromophore confers A/
T base pair requirement for intercalation and acts as DNA anchor
of amsacrine. Both constituents (methoxyaniline and acridine
chromophore) augment the binding specificity of amsacrine.
These findings are consistent with the observation that DNA
binding affinity of aminoacridine compounds are unaffected by
blockage of the major groove of the DNA while marked decrease
in their binding affinity was observed when minor groove binding
agent is added [42]. Amsacrine binding does not perturb
phosphate/phosphodiester vibrations of ctDNA and duplexes. It
is apparent by observation of phosphate and phosphodiester bands
in the 1250-1000cm1 region, which do not exhibit any significant
deviations. It implies that amsacrine orients itself in such a manner
that methoxyaniline moiety is away from backbone and simulta-
neously interacts with walls of minor grooves and thymine
C2=O2 group. In such a geometric orientation, where methox-
yaniline group is perpendicular to the plane of acridine
chromophore [43] and both moieties interact with base pairs
and minor groove; deep penetrations of base pairs is not possible
[20]. This explains why amsacrine is a weak DNA binder. A
QSAR (quantitative structure-activity relationship) study done by
Denny et al. further supports that groove-binding mode is essential
for biological activity of amsacrine [44]. Earlier studies show that
c-myc protooncogene is 20 times more susceptible for amsacrine-
mediated inhibition than global genome [16]. Topoisomerase 2
binding sites are preferentially found in c-myc transcription
regulatory regions. Therefore, differences in DNA sequence
selectivity exhibited by amsacrine here may contribute to the
selective antitumor activity of topoisomerase 2 inhibition (e.g.
inhibition of c-myc gene). Amsacrine binds with ctDNA in similar
fashion as with (AAAAAAAAAAAA)2 and (ATATATATA-
TAT)2, though DNA binding is weaker compared to these
duplexes. It is obvious by the given fact that
(AAAAAAAAAAAA)2 and (ATATATATATAT)2 offer better
minor groove which could accommodate methoxyaniline moiety
in a better way than groove of random sequence of ctDNA.
Amsacrine binding with (AGAGCAACAGAG)2 and (AGAGAC-
CAGAGA)2 sequences are weak due to the presence of alternating
guanine and adenine, which creates wider minor groove.
Moreover, guanine amino groups approaching in minor groove
of these sequences also hinder amsacrine interaction [45]. Binding
preference of amsacrine for all sequences studied here is found as:
(AAAAAAAAAAAA)2 < (ATATATATATAT)2. (ctDNA).(A-
GAGCAACAGAG)2 < (AGAGACCAGAGA)2. (TTAAT-
TAATTAA)2.
Effects of Amsacrine Binding on Local Conformation of
DNA
Antisymmetric PO2 stretching band (1225 cm
21) is a marker for
DNA in B conformation, regardless of base vibrations and sugar
pucker [31], [32]. This band did not show any appreciable shifts in
the spectra of complexes. As aforementioned, IR band at
839 cm21 is a fairly sensitive measure of S (C29-endo/anti) sugar
pucker and thus indicative of local DNA conformation. S (C29-
endo/anti) type sugar pucker corresponds to global B-DNA
conformation. Split into this band (,842 and ,824 cm21) and
presence of new shoulders around ,865and ,808 cm21 in the
complexes (Figure 3, 4) are indicative of some N type (C39-endo/
anti) sugar features in complexes [31], [33], [34]. N (C39-endo/
anti) type sugar pucker represents A-DNA conformation. Hence,
these features signify changes in local conformation of DNA and
coexistence of two different major sugar puckers (conformations)
upon interaction with amsacrine. Amsacrine induces similar kind
of structural changes in different sequences regardless of their
composition. It implies that rigid structure of amsacrine induces
local conformational changes in DNA to accommodate itself
between base pairs. In a recent study, similar results on
conformational alternations in DNA structure were observed for
9-amino-DACA, which alike to amsacrine, is an aminoacridine
derivative [46]. Conformation alternations induced by amsacrine
may change the major/minor groove ratio in the vicinity of
amsacrine intercalation and hence could bend or kink the DNA at
these sites. These fluctuations in DNA structure could be of high
importance because they may be sensed by topoisomerase 2 and
hence impart in formation and stabilization of ternary complexes.
It is proven by recent in vivo studies that DNA kinks and bend have
important role in the DNA binding by topoisomerases and thus
they create preferred binding sites for the enzyme [47].
During Intercalation, planer chromophore slides between two
base pairs without breaking Watson-Crick hydrogen bonds.
Chromophore of an intercalator interacts with adjacent base pairs
through pi stacking. These interactions have a stabilizing effect on
DNA’s structure, which leads to a raise in its melting temperature.
In groove binding mode, hydrogen bonding, Van der walls and
ionic interactions etc. occur between ligand and functional
group(s) of DNA. This mode of interaction also exerts stabilizing
effects on DNA structure. So overall, amsacrine interaction results
in enhanced stability of DNA helical structure. Although
amsacrine interaction results in local conformation change in
DNA, globally DNA helix remains in native B-DNA conforma-
tion. This is clear by no appreciable changes (shift and intensity) in
global conformational marker bands at 1225 cm21 and 970 cm21
in the spectra of complexes.
Minor Groove Width on Amsacrine-DNA Interaction
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Conclusions
Our results suggest that mixed-ligand type binding takes place
between amsacrine and DNA. These ATR-FTIR spectroscopic
analysis demonstrate that amsacrine binding with DNA requires
an A/T base pair and suitable minor groove and it is less sensitive
to direct read-out of DNA, therefore all AT rich sequences are not
equally favored. Minor groove interaction of amsacrine should
play a vital role in its cytotoxicity. Results obtained here for
amsacrine could be extended to other related anilinoacridines
which share amsacrine like pharmacophore.
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